Pharmaceutical Technology8d
AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment
The latest approval marks the fifth authorisation for AstraZeneca’s Tagrisso. Credit: © AstraZeneca 2024. AstraZeneca has gained approval from the European ...
Pharmaceutical Technology5d
Mankind Pharma and Innovent partner for Sintilimab commercialisation in India
Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock. Mankind Pharma has entered ...
Pharmaceutical Technology5d
Eisbach Bio positions HRD-targeting therapy to supplant PARP inhibitors
Eisbach Bio is developing EIS-12656, which works by inhibiting ALC1 (chromodomain-helicase-DNA-binding protein 1-like), a chromatin remodeller and DNA helicase also ...
Pharmaceutical Technology8d
Novo gets the green light for once-daily haemophilia drug following setbacks
Haemophilia is a rare condition that affects the blood’s ability to clot. Credit: Rembolle via Shutterstock. Novo Nordisk has secured approval from the US Food and Drug Administration (FDA) for Alhemo ...
Pharmaceutical Technology8d
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement
The agreement involves an anti-immunoglobulin E monoclonal antibody designed to treat various allergic conditions. Credit: Volha_R / Shutterstock. RAPT Therapeutics and Shanghai Jemincare ...
Pharmaceutical Technology6d
AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment
Datopotamab deruxtecan is intended for use in adults with locally advanced or metastatic nonsquamous NSCLC. Credit: New Africa/Shutterstock. AstraZeneca and Daiichi Sankyo have withdrawn their ...
Pharmaceutical Technology8d
GEMMABio raises $34m to advance gene therapy programmes
The $34m seed round was led by Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital. Credit: Gorodenkoff via Shutterstock. US-based gene therapy startup, GEMMABio has raised ...
Pharmaceutical Technology6d
Zastaprazan by Onconic Therapeutics for Gastric Ulcers: Likelihood of Approval
Zastaprazan is under clinical development by Onconic Therapeutics and currently in Phase III for Gastric Ulcers. According to GlobalData, Phase III drugs for Gastric Ulcers have an 86% phase ...
Pharmaceutical Technology6d
CTEcells by CTE Biologics for Chronic Traumatic Encephalopathy (CTE): Likelihood of Approval
CTEcells is under clinical development by CTE Biologics and currently in Phase II for Chronic Traumatic Encephalopathy (CTE). According to GlobalData, Phase II drugs for Chronic Traumatic ...
Pharmaceutical Technology6d
SPL-028 by Cybin for Generalized Anxiety Disorder (GAD): Likelihood of Approval
SPL-028 is under clinical development by Cybin and currently in Phase I for Generalized Anxiety Disorder (GAD). According to GlobalData, Phase I drugs for Generalized Anxiety Disorder (GAD) have an 81 ...
Pharmaceutical Technology6d
LM-302 by Bristol-Myers Squibb for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of ...
Pharmaceutical Technology7d
ACTUS-101 by Asklepios BioPharmaceutical for Pompe Disease: Likelihood of Approval
Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer AG, is a clinical-stage gene therapy company. It focuses on advancing genetic technology and developing life-saving adeno-associated virus ...